Swiss regulator approves Roche-Regeneron COVID-19 drug

Reuters

27 December 2021 - The Swiss medicines agency, Swissmedic, has given the green light to the monoclonal antibody cocktail Ronapreve developed by Roche and Regeneron for use in the treatment and prevention of COVID-19.

Ronapreve, a combination of two monoclonal antibodies (casirivimab and imdevimab), is approved for patients 12 years and up when “oxygen therapy or hospitalisation is not required and there is a high risk of developing a severe form of COVID-19," Swissmedic said in a statement.

Read SwissInfo article


Michael Wonder

Posted by:

Michael Wonder